Whether ASCT can be safely omitted from intensive first‐line therapy that incorporates a Bruton's tyrosine kinase (BTK) inhibitor, is being tested in the European MCL Network TRIANGLE trial (NCT02858258): ASCT after a rituximab/ibrutinib/Ara‐c containing induction in mantle cell lymphoma.55 The gene discussed is BTK; the disease is mantle cell lymphoma.